RGPX (Regenerex Pharma) Other Current Liabilities: $0.81 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenerex Pharma Other Current Liabilities?

Regenerex Pharma RGPX Other Current Liabilities is $0.81 Mil as of Sep. 2025.

Regenerex Pharma's other current liabilities for the quarter that ended in Sep. 2025 was $0.81 Mil.

Regenerex Pharma's quarterly other current liabilities increased from Mar. 2025 ($0.00 Mil) to Jun. 2025 ($0.86 Mil) but then declined from Jun. 2025 ($0.86 Mil) to Sep. 2025 ($0.81 Mil).

Regenerex Pharma's annual other current liabilities declined from Mar. 2023 ($0.00 Mil) to Mar. 2024 ($-0.00 Mil) but then increased from Mar. 2024 ($-0.00 Mil) to Mar. 2025 ($0.00 Mil).

Regenerex Pharma Other Current Liabilities Related Terms

Regenerex Pharma Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Regenerex Pharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerex Pharma Other Current Liabilities Chart

Regenerex Pharma Annual Data
Trend Nov14 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 0.00 -0.00 0.00

Regenerex Pharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.80 0.00 0.86 0.81

Regenerex Pharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.81 Mil mean?
Regenerex Pharma (RGPX) has a Other Current Liabilities of $0.81 Mil as of Sep. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Regenerex Pharma.
Is Regenerex Pharma's Other Current Liabilities too high?
Regenerex Pharma's current Other Current Liabilities is $0.81 Mil.
How does Regenerex Pharma's Other Current Liabilities compare to CABN and TEKXD?
Regenerex Pharma's Other Current Liabilities of $0.81 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Regenerex Pharma. Regenerex Pharma's current Other Current Liabilities is $0.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerex Pharma stock overvalued right now?
Regenerex Pharma (RGPX) has a current Other Current Liabilities of $0.81 Mil. The current Other Current Liabilities is $0.81 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Regenerex Pharma (RGPX), the current Other Current Liabilities is $0.81 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerex Pharma Business Description

Address 5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108
Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.